These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Selective inhibitors of picornavirus replication. De Palma AM; Vliegen I; De Clercq E; Neyts J Med Res Rev; 2008 Nov; 28(6):823-84. PubMed ID: 18381747 [TBL] [Abstract][Full Text] [Related]
4. Antiviral therapy for enteroviruses and rhinoviruses. Rotbart HA Antivir Chem Chemother; 2000 Jul; 11(4):261-71. PubMed ID: 10950388 [TBL] [Abstract][Full Text] [Related]
5. Treatment of picornavirus infections. Rotbart HA Antiviral Res; 2002 Feb; 53(2):83-98. PubMed ID: 11750935 [TBL] [Abstract][Full Text] [Related]
6. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Ramajayam R; Tan KP; Liang PH Biochem Soc Trans; 2011 Oct; 39(5):1371-5. PubMed ID: 21936817 [TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Bauer L; Lyoo H; van der Schaar HM; Strating JR; van Kuppeveld FJ Curr Opin Virol; 2017 Jun; 24():1-8. PubMed ID: 28411509 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Barnard DL; Hubbard VD; Smee DF; Sidwell RW; Watson KG; Tucker SP; Reece PA Antimicrob Agents Chemother; 2004 May; 48(5):1766-72. PubMed ID: 15105133 [TBL] [Abstract][Full Text] [Related]
11. Picornavirus infections: a primer for the practitioner. Rotbart HA; Hayden FG Arch Fam Med; 2000; 9(9):913-20. PubMed ID: 11031400 [TBL] [Abstract][Full Text] [Related]
12. Progress in human picornavirus research: New findings from the AIROPico consortium. Wolthers KC; Susi P; Jochmans D; Koskinen J; Landt O; Sanchez N; Palm K; Neyts J; Butcher SJ Antiviral Res; 2019 Jan; 161():100-107. PubMed ID: 30472162 [TBL] [Abstract][Full Text] [Related]
13. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Norder H; De Palma AM; Selisko B; Costenaro L; Papageorgiou N; Arnan C; Coutard B; Lantez V; De Lamballerie X; Baronti C; SolĂ M; Tan J; Neyts J; Canard B; Coll M; Gorbalenya AE; Hilgenfeld R Antiviral Res; 2011 Mar; 89(3):204-18. PubMed ID: 21236302 [TBL] [Abstract][Full Text] [Related]
14. Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections. Wang QM Prog Drug Res; 2001; Spec No():229-53. PubMed ID: 11548209 [TBL] [Abstract][Full Text] [Related]
15. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Bernard A; Lacroix C; Cabiddu MG; Neyts J; Leyssen P; Pompei R Antivir Chem Chemother; 2015 Apr; 24(2):56-61. PubMed ID: 26071135 [TBL] [Abstract][Full Text] [Related]
16. Enterovirus infections with special reference to enterovirus 71. Hsiung GD; Wang JR J Microbiol Immunol Infect; 2000 Mar; 33(1):1-8. PubMed ID: 10806956 [TBL] [Abstract][Full Text] [Related]
17. Picornavirus and enterovirus diversity with associated human diseases. Tapparel C; Siegrist F; Petty TJ; Kaiser L Infect Genet Evol; 2013 Mar; 14():282-93. PubMed ID: 23201849 [TBL] [Abstract][Full Text] [Related]
18. The enteroviruses: problems in need of treatments. Abzug MJ J Infect; 2014 Jan; 68 Suppl 1():S108-14. PubMed ID: 24119825 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Hayden FG; Herrington DT; Coats TL; Kim K; Cooper EC; Villano SA; Liu S; Hudson S; Pevear DC; Collett M; McKinlay M; Clin Infect Dis; 2003 Jun; 36(12):1523-32. PubMed ID: 12802751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]